Comprehensive information about experimentally validated enhancers
| Enhancer ID: | E_03615 |
| Species: | Homo sapiens |
| Position : | chr12:6933000-6941000 |
| Year: | 2025 |
| Title: | LNP-enclosed NamiRNA inhibits pancreatic cancer proliferation and migration via dual pathways. |
| Genome Build: | hg38 |
| Enhancer Type: | Enhancer |
| Condition: | Disease |
| Disease Name: | pancreatic ductal adenocarcinoma |
| PMID: | 40611281 |
| MONDO: | MONDO:0005184 |
| Tissue: | pancreas |
| Tissue Ontology ID: | UBERON:0001264 |
| Cell Source: | MIA PaCa-2 |
| CVCL ID: | CVCL_0428 |
| Cell Type: | malignant cell |
| Cell Ontology ID: | CL:0001064 |
| Experiment Type: | Enhancer activity assay, Functional perturbation assay, TF binding assay; In vivo functional validation |
| High Throughput Method: | ChIP-seq, RNA-seq |
| Low Throughput Method: | Luciferase Reporter Assay, CRISPR Knockout, ChIP-RT-qPCR, qRT-PCR, Western blot; In vivo phenotyping |
| Target gene : | PTPN6 |
| TF name : | NA |
| Regulatory State : | Active |
| GeneName | Pathway Name | Source | Gene Number |
|---|